TB 796
Alternative Names: TB-796Latest Information Update: 26 Aug 2024
Price :
$50 *
At a glance
- Originator Twinpig Biolab
- Class Peptides
- Mechanism of Action Insulin-like growth factor I inhibitors; Macrophage modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Sarcopenia
Most Recent Events
- 01 Aug 2024 Phase-II clinical trials in Sarcopenia (Parenteral) prior to August 2024 (Twinpig Biolab pipeline, August 2024)
- 01 Aug 2024 Twinpig Biolab anticipates approval of TB 796 in Sarcopenia, by 2026 (Twinpig Biolab pipeline, August 2024)
- 01 Aug 2024 Pharmacodynamics data from preclinical studies in Sarcopenia released by Twinpig Biolab (Twinpig Biolab pipeline, August 2024)